Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
PLoS One ; 15(6): e0234271, 2020.
Article in English | MEDLINE | ID: mdl-32525925

ABSTRACT

OBJECTIVES: Antiplatelet therapy following peripheral arterial endovascular intervention lacks high quality evidence to guide practice. The aim of this study was to assess the effect of three months of dual antiplatelet therapy on amputation-free survival following peripheral arterial endovascular intervention in patients with chronic limb threatening ischemia. METHODS: A retrospective review of symptomatic patients undergoing primary peripheral arterial endovascular intervention over a seven-year period was performed. The primary outcome measure was amputation-free survival. A sample size calculation based on previous cohort studies suggested that 629 limbs would be required to show a difference between single and dual therapy. Kaplan-Meier estimates and multivariate logistic regression analysis of recorded baseline characteristics was performed to determine predictors of amputation-free survival. Dual antiplatelet therapy was routinely given for 3 months. RESULTS: 754 limbs were treated with primary angioplasty and/or stenting over a 7-year period, 508 of these for chronic limb threatening ischemia. There was no difference in unadjusted amputation-free survival between patients with chronic limb threatening ischaemia taking single vs. dual antiplatelet therapy (69% vs. 74% respectively Log rank Chi2 = 0.1, p = .72). After adjusting for confounders, at 1 year there was also no significant difference in amputation-free survival between patients taking single vs. dual antiplatelet therapy [OR 0.8, 95% CI 0.5-1.2, p = .3]. There was no difference in rates of major bleeding between single and dual antiplatelet therapy. CONCLUSIONS: There was no clear evidence of reduced amputation-free survival in patients with chronic limb threatening ischemia undergoing peripheral arterial endovascular intervention being treated with dual antiplatelet therapy for 3 months. This is at odds with other retrospective case series and highlights the limitations in basing clinical practice on such data. There is a need for an adequately powered, independent randomised trial to definitively answer the question.


Subject(s)
Endovascular Procedures , Ischemia/drug therapy , Ischemia/surgery , Lower Extremity/blood supply , Platelet Aggregation Inhibitors/pharmacology , Aged , Cohort Studies , Female , Humans , Kaplan-Meier Estimate , Male , Platelet Aggregation Inhibitors/therapeutic use , Retrospective Studies , Survival Analysis
2.
3.
Health Technol Assess ; 19(32): 1-154, v-vi, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25924187

ABSTRACT

BACKGROUND: Abdominal aortic aneurysm (AAA) repair aims to prevent premature death from AAA rupture. Elective repair is currently recommended when AAA diameter reaches 5.5 cm (men) and 5.0 cm (women). Applying population-based indications may not be appropriate for individual patient decisions, as the optimal indication is likely to differ between patients based on age and comorbidities. OBJECTIVE: To develop an Aneurysm Repair Decision Aid (ARDA) to indicate when elective AAA repair optimises survival for individual patients and to assess the cost-effectiveness and associated uncertainty of elective repair at the aneurysm diameter recommended by the ARDA compared with current practice. DATA SOURCES: The UK Vascular Governance North West and National Vascular Database provided individual patient data to develop predictive models for perioperative mortality and survival. Data from published literature were used to model AAA growth and risk of rupture. The cost-effectiveness analysis used data from published literature and from local and national databases. METHODS: A combination of systematic review methods and clinical registries were used to provide data to populate models and inform the structure of the ARDA. Discrete event simulation (DES) was used to model the patient journey from diagnosis to death and synthesised data were used to estimate patient outcomes and costs for elective repair at alternative aneurysm diameters. Eight patient clinical scenarios (vignettes) were used as exemplars. The DES structure was validated by clinical and statistical experts. The economic evaluation estimated costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) from the NHS, social care provider and patient perspective over a lifetime horizon. Cost-effectiveness acceptability analyses and probabilistic sensitivity analyses explored uncertainty in the data and the value for money of ARDA-based decisions. The ARDA outcome measures include perioperative mortality risk, annual risk of rupture, 1-, 5- and 10-year survival, postoperative long-term survival, median life expectancy and predicted time to current threshold for aneurysm repair. The primary economic measure was the ICER using the QALY as the measure of health benefit. RESULTS: The analysis demonstrated it is feasible to build and run a complex clinical decision aid using DES. The model results support current guidelines for most vignettes but suggest that earlier repair may be effective in younger, fitter patients and ongoing surveillance may be effective in elderly patients with comorbidities. The model adds information to support decisions for patients with aneurysms outside current indications. The economic evaluation suggests that using the ARDA compared with current guidelines could be cost-effective but there is a high level of uncertainty. LIMITATIONS: Lack of high-quality long-term data to populate all sections of the model meant that there is high uncertainty about the long-term clinical and economic consequences of repair. Modelling assumptions were necessary and the developed survival models require external validation. CONCLUSIONS: The ARDA provides detailed information on the potential consequences of AAA repair or a decision not to repair that may be helpful to vascular surgeons and their patients in reaching informed decisions. Further research is required to reduce uncertainty about key data, including reintervention following AAA repair, and assess the acceptability and feasibility of the ARDA for use in routine clinical practice. FUNDING: The National Institute for Health Research Health Technology Assessment programme.


Subject(s)
Decision Support Techniques , Elective Surgical Procedures/economics , State Medicine/economics , Vascular Surgical Procedures/economics , Age Factors , Aged , Aortic Aneurysm, Abdominal/economics , Cost-Benefit Analysis , Female , Health Status , Humans , Kaplan-Meier Estimate , Life Expectancy , Male , Middle Aged , Models, Econometric , Perioperative Period/mortality , Quality-Adjusted Life Years , Risk Factors , Sex Factors
4.
Exp Clin Transplant ; 11(6): 558-61, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24344947

ABSTRACT

Graft site candidiasis is a rare but life-threatening complication of renal transplant. We report the course and management of 2 renal transplant recipients, using kidneys from a single donor, both of whom developed vascular complications secondary to Candida infection.


Subject(s)
Arteritis/microbiology , Candida albicans , Candidiasis/complications , Kidney Transplantation , Transplantation , Aged , Antifungal Agents/therapeutic use , Arteritis/diagnosis , Candidiasis/diagnosis , Candidiasis/drug therapy , Fluconazole/therapeutic use , Humans , Kidney Failure, Chronic/surgery , Male , Middle Aged , Nephrectomy , Renal Insufficiency/surgery , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...